ChangAn Opens First International NEV Manufacturing Base in Thailand, Expanding Its Industry Export Model
RAYONG, Thailand, May 19, 2025 /PRNewswire/ -- ChangAn Automobile ("ChangAn" or "the Company"), an intelligent low-carbon mobility technology company, has accelerated its Vast Ocean Plan for global expansion with the launch of production at its first international new energy vehicle (NEV) production base in Rayong, Thailand. The facility marks a transition from product exports to exporting entire industrial ecosystems. The Rayong factory incorporates manufacturing systems, R&D processes, and supply chain standards, establishing a green, intelligent, and replicable model for sustainable global operations.
Coinciding with the launch of the Rayong factory, ChangAn also celebrated the rollout of its 28.59 millionth vehicle, a right-hand drive DEEPAL S05 tailored for global markets. This milestone underscores ChangAn's commitment to its Vast Ocean Plan, which aims to elevate five major overseas markets—Southeast Asia, the Middle East and Africa, Central and South America, Europe, and Eurasia—to the same strategic level as its home market in China. By scaling globally with smart manufacturing and localised collaboration, ChangAn is accelerating its transformation into a world-class automobile brand.
The Rayong factory spans approximately 245 rai (392,000 square meters), and boasts five workshops, including welding, painting, general assembly, engine assembly, and battery, plus auxiliary functions such as exterior inspection. As a green, energy-efficient facility, it features streamlined operations with daylight optimisation, photovoltaic systems, and greywater/rainwater recycling, reducing per-vehicle energy consumption by around 20%. Automated processes, adaptive conveyance systems, and advanced assembly and testing ensure production efficiency and product quality for diverse market demands. In the future, the CHANG-AN, DEEPAL, and AVATR brands will be produced at the Rayong Factory, with annual capacity expected to double from 100,000 to 200,000 units by 2027.
ChangAn's Vast Ocean Plan reflects global industry trends, with the Rayong Factory marking a major step in its international operation. To date, ChangAn has held brand launches in Mexico, Saudi Arabia, and Germany. In particular, since launching its Southeast Asia brand initiative in Thailand in November 2023, the company has introduced seven new models to the Thai market including the DEEPAL S07, E07, and AVATR 11, with cumulative sales exceeding 14,000 units, ranking among the top four in Thailand's NEV market.
ChangAn's Rayong factory marks the culmination of 41 years of automotive manufacturing expertise. Blending this legacy with local operations, the facility has established a global system standard cultivating international talent. It sets the foundation for replicating ChangAn's global factory standards and serves as a best-practice model for international operations, reflected in four key areas, namely, the application of ChangAn's CPS lean manufacturing system, emphasising leadership, productivity, and performance. The integration of seven operational systems and six core processes forms the core of the Company's lean management strategy, reflecting its commitment to excellence. Leveraging the CAPDS system, the plant strengthens Southeast Asian technical support and engineering development. It focuses on new energy, intelligent systems, adaptive design, and advancing regional product innovation. Built on the CA-PLS framework, Rayong is ChangAn's first international site to standardise production management enabling rapid product launches. The plant marks an innovative, resilient, dual-circulation supply chain linking China and Thailand.
"This is a big moment for ChangAn – a giant leap from exporting cars to building local ecosystem," said Zhu Huarong, Chairman of ChangAn Automobile. "Despite the huge challenges brought by anti-globalization, ChangAn stays committed to Vast Ocean Plan. With a spirit of win-win cooperation, we will contribute more to economic and social development of Thailand, and drive the global auto industry forward."
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Korea Herald
an hour ago
- Korea Herald
J INTS BIO to Present Global Clinical Results from JIN-A02, a Fourth-Generation EGFR-TKI, at ASCO 2025
Significant anti-tumor responses and reduction of brain metastases observed SEOUL, South Korea , June 2, 2025 /PRNewswire/ -- J INTS BIO, a company specializing in the development of therapeutics for cancer and rare diseases, officially announced interim results from the global Phase 1/2 clinical trial of JIN-A02, its fourth-generation EGFR-TKI drug candidate, at the American Society of Clinical Oncology 2025 (ASCO 2025), the world's largest oncology conference, held in Chicago, USA. JIN-A02 is an oral, fourth-generation EGFR-TKI designed to overcome resistance mutations (such as C797S) that develop after treatment failure with third-generation EGFR-TKIs, which are currently the first-line therapy for EGFR-mutant Non-small cell lung cancer (NSCLC). It is currently undergoing clinical trials in South Korea, the United States, Thailand, and other countries. Key efficacy and safety results from Part A (dose escalation) of the multi-center clinical trial (NCT05394831) were presented. 'Confirmed' clinical response observed in patients with disease progression after 3 rd Generation EGFR TKI and chemotherapy One of the key findings of the ASCO presentation was that tumor responses were sustained in specific dose cohorts, with confirmed partial responses (PRs) verified by independent evaluation. Confirmed PRs were observed in 50mg,100mg and 300mg QD dose groups, providing clinical evidence of anti-tumor activity. In the 50 mg dose group, patients achieved a 77.3% reduction in tumor size, maintaining a PR over six consecutive treatment cycles (from cycle 3 to cycle 13). In the 300 mg dose group, a confirmed PR was observed with a 39.7% tumor size reduction, including a significant reduction in brain metastatic lesions. In the 100 mg dose group, a PR was also reported with a 35.3% reduction in tumor size, and brain metastatic lesions remained stable, further supporting the potential of JIN-A02 in treating brain metastases. Safety confirmed up to 300 mg, with therapeutic signals in brain metastases No dose-limiting toxicities (DLTs) or serious adverse events were observed with JIN-A02 at doses up to 300mg, which is six times the dose level when PR was first observed, demonstrating a favorable safety profile even at higher dose levels. The majority of adverse events reported at 300mg were mild (Grade 1-2) and included for the first time, Grade 1 skin rash, diarrhea, and skin desquamation in 3 out of 5 subjects – events commonly associated with EGFR inhibitors and generally considered clinically manageable. Importantly, there were no reports of systemic toxicities such as cardiovascular events or hepatotoxicity, supporting the drug's excellent safety profile. This safety and tolerability have translated into extended treatment durations in real-world settings, with a patient still on JIN-A02 after one year and seven months. In addition, the trial demonstrated notable responses in brain metastases first noted at 100mg, suggesting that JIN-A02 achieves therapeutically relevant concentrations in brain tissue. JIN-A02 gains national spotlight as government grants accelerate development In addition to the ASCO announcement, J INTS BIO continues to achieve noteworthy results in Korea. Recently, it was selected for the '2025 Baby Unicorn Fostering Project' by the Ministry of SMEs and Startups, officially recognizing both our scientific technology and commercialization potential. The 'Baby Unicorn Fostering Project' is a government project that focuses on developing promising startups with innovative technologies and growth potential in the global market as 'potential unicorns'. Companies selected for this project will receive full government support in recognition of their technological prowess and growth potential. With these accolades, JIN-A02 will receive dual funding for its Phase 2 trial and global expansion over the next two years, which is expected to be a decisive point to significantly accelerate the pace of clinical and commercialization in parallel with private investment. It is also significant as a case of securing confidence in the 3 arena of technology, marketability, and global scalability, as the recognition came from different government departments. Based on these achievements, we plan to initiate the Phase 2 clinical trial of JIN-A02 in before the end of this year, in discussions with the US FDA. "The ASCO presentation of JIN-A02's ability to induce anti-cancer responses and its ability to respond to central nervous system metastatic lesions is of great significance," said Dr. Anna Jo, CEO. "The government's continued support is a recognition of our technical capabilities and potential for growth. We will take advantage of this opportunity to accelerate global clinical expansion, technology transfer, and indication expansion to realize our goal of early commercialization"
Korea Herald
a day ago
- Korea Herald
Tianfu Rapoil Shines at Hong Kong Hometown Market Carnival
HONG KONG, June 1, 2025 /PRNewswire/ -- This is a report from Xinhuanet: Co-organized by 30 provincial-level hometown associations in Hong Kong, the "Third Hometown Market Carnival" was kicked off on June 1 in Victoria Park, marking the beginning of the five-day event. The Sichuan Provincial Grain and Material Reserve Bureau showcased its premium products under the 'Tianfu Rapoil' brand at the event, becoming the star attraction in this year. At the event, Tianfu Rapoil brought nearly 2,000 products, ranging from 'Traditional Small-Pressed Rich-Aromatic Rapeseed Oil' made using non-heritage pressing techniques, to low-erucic acid rapeseed oil, and small-packaged rapeseed oil specifically designed for younger consumers. On-site, residents and tourists participated in 'Come to Play and Win Oil in Victoria Park'. They not only won Tianfu Rapoil products but also received its limited-edition cultural and creative merchandise. Items such as umbrellas, folding fans, and canvas bags featuring panda patterns became the most sought-after items at the event. This year's Hong Kong Hometown Market Carnival features a special Chinese Food Street, with 30 food stalls offering cuisines from all over China. When Tianfu Rapoil meets regional specialities such as Xinjiang lamb skewers, Shaanxi Roujiamo, and Hunan Changde rice noodles, magical sparks occur. At Xinjiang association stall, chefs blended Tianfu rapeseed oil with cumin and chili powder to create a secret sauce brushed onto sizzling lamb skewers, drawing a snaking line of eager customers. At Shaanxi association stall, chefs tried Tianfu rapeseed oil to bake Roujiamo, praised by diners as a 'soulful carb bomb'. At Hunan association stall, chefs used Tianfu rapeseed oil to prepare the special topping for Changde rice noodles, delighting noodle lovers with its fragrant and refreshing taste. During the event, procurement managers from local Hong Kong catering groups and buyers from high-end supermarkets were drawn by the aroma. "The fragrance of Tianfu Rapoil is unique. After testing it in cooking, we noticed a significant improvement in the dishes' flavor," said a procurement representative from a well-known chain restaurant, who expressed immediate interest in establishing a stable supply channel after learning about the oil's production process and quality standards. The flood of partnership inquiries reflects the robust strength of Sichuan's rapeseed industry. As the province with the largest rapeseed cultivation area and the highest rapeseed oil consumption in China, Sichuan has in recent years taken the Tianfu Rapoil initiative as a starting point to drive the upgrading of the entire industrial chain, and enabled Tianfu Rapoil to stand out in the domestic edible oil sector, winning the 'China Grain and Oil Influential Public Brand' award for five consecutive years, with a brand value exceeding 10 billion yuan.
Korea Herald
a day ago
- Korea Herald
Fall of Mongolian coalition government could lead to severe economic downturn
ULAANBAATAR, Mongolia, June 1, 2025 /PRNewswire/ -- As Mongolia's parliament prepares to vote on Monday on whether the country's coalition government should remain in office, new economic analysis warns that the demise of the government could see the size of Mongolia's economy contract by over 20% within six months, and FDI fall by almost 40% year-on-year. Prime Minister Oyun-Erdene called on Wednesday for members of the Great State Khural to decide on whether the coalition government, which has been in place since last June's parliamentary elections, should remain as a way of ending recent political instability. The Prime Minister is due to address the Khural on Monday ahead of a 'confidence vote' – likely to be deemed one of the most important moments in Mongolia's political history since becoming a democracy in the early 1990s. As the vote approaches, new economic data – which can be viewed in full here – produced by Mongolia's Economic Development Board warns of the scale of the economic hit Mongolia could face, namely: These forecasts are in line with the experiences of other countries where political instability has had a negative impact on the economy, including following the fall of a coalition government: Commenting, Dr Batnasan B., Professor at the Business School of the National University of Mongolia and Member of the Economic Development Board, said: " The latest data clearly highlights the potential economic consequences of a collapse in Mongolia's coalition government: a sharp economic downturn, runaway inflation, and a rise in unemployment. "It is entirely appropriate that elected representatives decide who governs the country. But it is equally important that such decisions are made with full access to the facts and a clear understanding of the potential risks. "The Economic Development Board's analysis—combined with lessons from other countries that have faced similar circumstances—presents a compelling warning: all the hard-won economic progress Mongolia has achieved in recent years could be jeopardized if Monday's vote results in increased political instability." This new analysis, as well as precedent from around the world, clearly shows the magnitude of the decision to be taken by lawmakers on Monday, and the jeopardy to the significant economic progress Mongolia has made since the COVID-19 pandemic, including adding $9 billion USD to its economy and increasing GDP per capita by an additional $2,400.
